182 related articles for article (PubMed ID: 17472691)
21. Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series.
Ruiz-Villaverde R; Sánchez-Cano D; Burkhardt-Pérez P
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):828-31. PubMed ID: 19646136
[TBL] [Abstract][Full Text] [Related]
22. Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study.
van der Geer S; Martens J; van Roij J; Brand E; Ostertag JU; Verhaegh ME; Neumann HA; Krekels GA
Br J Dermatol; 2012 Jul; 167(1):110-5. PubMed ID: 22385074
[TBL] [Abstract][Full Text] [Related]
23. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient.
Kagy MK; Amonette R
Dermatol Surg; 2000 Jun; 26(6):577-8; discussion 578-9. PubMed ID: 10848940
[TBL] [Abstract][Full Text] [Related]
24. An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream.
Cowen E; Mercurio MG; Gaspari AA
J Am Acad Dermatol; 2002 Oct; 47(4 Suppl):S240-8. PubMed ID: 12271286
[TBL] [Abstract][Full Text] [Related]
25. [How I treat ... basal cell carcinoma by imiquimod].
Piérard-Franchimont C; Nikkels AF; Paquet P; Quatresooz P; Piérard GE
Rev Med Liege; 2005 Apr; 60(4):207-9. PubMed ID: 15943094
[TBL] [Abstract][Full Text] [Related]
26. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
27. Imiquimod in dermatology: an overview.
Hanna E; Abadi R; Abbas O
Int J Dermatol; 2016 Aug; 55(8):831-44. PubMed ID: 27387373
[TBL] [Abstract][Full Text] [Related]
28. Vasodilatory adverse events associated with topical imiquimod 5 percent cream.
Jacobs AA; Snavely N; Markus J; Rosen T
Dermatol Online J; 2008 Apr; 14(4):4. PubMed ID: 18627726
[TBL] [Abstract][Full Text] [Related]
29. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle.
Berman B; Sullivan T; De Araujo T; Nadji M
Br J Dermatol; 2003 Nov; 149 Suppl 66():59-61. PubMed ID: 14616354
[TBL] [Abstract][Full Text] [Related]
30. Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.
Papadavid E; Stratigos AJ; Falagas ME
Expert Opin Pharmacother; 2007 Aug; 8(11):1743-55. PubMed ID: 17685890
[TBL] [Abstract][Full Text] [Related]
31. Multiple superficial basal cell carcinomata--topical imiquimod versus curette and cryotherapy.
Dixon AJ
Aust Fam Physician; 2005; 34(1-2):49-52. PubMed ID: 15727358
[TBL] [Abstract][Full Text] [Related]
32. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
33. Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma.
Graells J; Ojeda RM; García-Cruz A
Actas Dermosifiliogr; 2014; 105(1):53-9. PubMed ID: 24139468
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review.
Lacarrubba F; Potenza MC; Gurgone S; Micali G
J Dermatolog Treat; 2011 Dec; 22(6):353-8. PubMed ID: 21781010
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream.
Beutner KR; Geisse JK; Helman D; Fox TL; Ginkel A; Owens ML
J Am Acad Dermatol; 1999 Dec; 41(6):1002-7. PubMed ID: 10570388
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.
Garcia-Martin E; Idoipe M; Gil LM; Pueyo V; Alfaro J; Pablo LE; Zubiri ML; Fernandez J
J Ocul Pharmacol Ther; 2010 Aug; 26(4):373-9. PubMed ID: 20698800
[TBL] [Abstract][Full Text] [Related]
37. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
38. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe.
Gollnick H; Barona CG; Frank RG; Ruzicka T; Megahed M; Tebbs V; Owens M; Stampone P
Eur J Dermatol; 2005; 15(5):374-81. PubMed ID: 16172048
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma.
Bostanci S; Kocyigit P; Vural S; Heper AO; Botsali A
Dermatol Surg; 2018 Jan; 44(1):36-41. PubMed ID: 29016542
[TBL] [Abstract][Full Text] [Related]
40. Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.
Gaitanis G; Bassukas ID
Acta Derm Venereol; 2014 Jan; 94(1):38-44. PubMed ID: 23722308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
